Modern basal insulins: an ongoing story or the start of a new era?
https://doi.org/10.14341/DM7693
Abstract
Basal insulin represents an essential tool in the treatment of both type 1 and type 2 diabetes mellitus. The development of insulin analogues has improved the possibilities of diabetes treatment. Despite significant progress in understanding the physiology, chemistry, kinetics and action of insulin, currently available basal insulin products do not optimally mimic the endogenous profile of insulin. Although basal insulin analogues have some advantages over neutral protamine Hagedorn insulin in diabetes treatment, hypoglycaemia remains the main problem in the achievement of optimal glycaemic control in most patients with diabetes. These unmet clinical needs have stimulated the development of new basal insulin analogues with improved pharmacological profiles. This article reviews the specific characteristics of new long-acting insulin analogues to try and understand their benefits and limitations in the improvement of diabetes management and their possibilities in physiologic and safe insulin replacement.
About the Author
Ivan Ivanovich Dedov
Endocrinology Research Centre
Russian Federation
MD, PhD, Professor, Deputy president of the Russian Academy of sciences
Competing Interests: Автор дикларирует отсутствие конфликта интересов
Russian Federation
MD, PhD, Professor, Deputy president of the Russian Academy of sciences
Competing Interests: Автор дикларирует отсутствие конфликта интересов
References
1. Шестакова М.В. Реальная клиническая практика лечения сахарного диабета 2 типа в Российской Федерации по данным открытой проспективной наблюдательной программы «ДИА-КОНТРОЛЬ». // Сахарный диабет. – 2011. – Т. 14. – №4 – С.75-80. [Shestakova MV. Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospective observational study DIA-CONTROL. Diabetes mellitus. 2011;14(4):75-80. (in Russ)] doi: 10.14341/2072-0351-5822
2. Berger M. Практика инсулинотерапии / Под ред. Старостиной Е.Г., Дедова И.И. Первое русское издание. – Berlin:Springer-Verlag; 1990. [Berger M. Praktika insulinoterapii. Ed. by Starostina E.G., Dedov I.I. First Russian Edition. Berlin: Springer-Verlag; 1990. (in Russ)].
3. Tibaldi JM. Evolution of insulin development: focus on key parameters. Advances in therapy. 2012;29(7):590-619. doi: 10.1007/s12325-012-0034-8
4. Garber AJ. Restaging insulin therapy for patients with type 2 diabetes. Diabetes, obesity & metabolism. 2009;11 Suppl 5:1-5. doi: 10.1111/j.1463-1326.2009.01136.x
5. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes, Obesity & Metabolism. 2007;9(5):648-659. doi: 10.1111/j.1463-1326.2007.00756.x
6. Mullins P, Sharplin P, Yki-Jarvinen H, et al. Negative Binomial Meta-Regression Analysis of Combined Glycosylated Hemoglobin and Hypoglycemia Outcomes Across Eleven Phase III and IV Studies of Insulin Glargine Compared with Neutral Protamine Hagedorn Insulin in Type 1 and Type 2 Diabetes Mellitus. Clinical Therapeutics.2007;29(8):1607-1619. doi: 10.1016/j.clinthera.2007.08.020
7. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes, obesity & metabolism. 2009;11(4):372-378. doi: 10.1111/j.1463-1326.2008.00976.x
8. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. The Cochrane database of systematic reviews. 2007;(2):CD005613. doi: 10.1002/14651858.CD005613.pub3
9. Szypowska A, Golicki D, Groele L, Pankowska E. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis. Polskie Archiwum Medycyny Wewnetrznej. 2011;121(7-8):237-246.
10. Tricco AC, Ashoor HM, Antony J, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ. 2014;349:g5459. doi: 10.1136/bmj.g5459
11. Koehler G, Treiber G, Wutte A, et al. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Diabetes, obesity & metabolism. 2014;16(1):57-62. doi: 10.1111/dom.12178
12. DeVries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes/metabolism research and reviews. 2007;23(6):441-454. doi: 10.1002/dmrr.762
13. Garg SK, Gottlieb PA, Hisatomi ME, et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.Diabetes research and clinical practice. 2004;66(1):49-56. doi: 10.1016/j.diabres.2004.02.008
14. Marre M, Pinget M, Gin H, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes. Diabetes & metabolism. 2009;35(6):469-475. doi: 10.1016/j.diabet.2009.06.004
15. Investigators OT, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. The New England Journal of Medicine. 2012;367(4):319-328. doi: 10.1056/NEJMoa1203858
16. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53(9):787-800. doi: 10.1007/s40262-014-0165-y
17. Korsatko S, Deller S, Mader JK, et al. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. Drugs & aging. 2014;31(1):47-53. doi: 10.1007/s40266-013-0138-0
18. Biester T, Blaesig S, Remus K, et al. Insulin degludec’s ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatric diabetes. 2014;15(1):27-33. doi: 10.1111/pedi.12116
19. Kupcova V, Arold G, Roepstorff C, et al. Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. Clinical drug investigation. 2014;34(2):127-133. doi: 10.1007/s40261-013-0154-1
20. Kiss I, Arold G, Roepstorff C, et al. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2014;53(2):175-183. doi: 10.1007/s40262-013-0113-2
21. Funakoshi S, Hashiguchi J, Komine M, et al. Superior glycaemic control effects with insulin degludec (IDeg) to insulin glargine (IGlar) in diabetic hemodialysis (HD) patients assessed by continuous glucose monitoring (CG M) (63-OR).Ned Tijdschr Diabet. 2014;12(4):16-16. doi: 10.1007/s12467-014-0037-y
22. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes, obesity & metabolism. 2013;15(2):175-184. doi: 10.1111/dom.12032
23. Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes therapy. 2014;5(2):435-446. doi: 10.1007/s13300-014-0076-9
24. Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: What progress have we made? Diabetes/metabolism research and reviews. 2014;30(2):104-119. doi: 10.1002/dmrr.2469
25. Russell-Jones D, Gall MA, Niemeyer M, et al. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. Nutrition, metabolism, and cardiovascular diseases. NMCD. 2015;25(10):898-905. doi: 10.1016/j.numecd.2015.06.005
26. Jørgensen KH, Hansen AK, Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract. 2000;50(3):161-167. doi: 10.1016/s0168-8227(00)00196-0.
27. Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clinical drug investigation. 2013;33(7):515-521. doi: 10.1007/s40261-013-0096-7
28. Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes care. 2013;36(9):2536-2542. doi: 10.2337/dc12-2329
29. Steinstraesser A, Schmidt R, Bergmann K, et al. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes, obesity & metabolism. 2014;16(9):873-876. doi: 10.1111/dom.12283
30. Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 Units. mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units. mL-1. Diabetes care. 2015;38(4):637-643. doi: 10.2337/dc14-0006
31. Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.Diabetes, obesity & metabolism. 2015;17(9):859-867. doi: 10.1111/dom.12485
32. Home PD, Bergenstal RM, Bolli GB, et al. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes care. 2015;38(12):2217-2225. doi: 10.2337/dc15-0249.
33. Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск). // Сахарный диабет. – 2015. – Т. 18. – №1S. – С.1-112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). Diabetes mellitus. 2015;18(1S):1-112. (in Russ)] doi: 10.14341/DM20151S1-112
Supplementary files
Review
For citations:
Dedov I.I. Modern basal insulins: an ongoing story or the start of a new era? Diabetes mellitus. 2015;18(4):5-11. (In Russ.) https://doi.org/10.14341/DM7693
Views:
20299
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
